Abstract Preneoplastic lesions (aberrant crypt foci, hyperplastic/dysplastic polyps) are believed to be precursors of sporadic colorectal tumors (adenomas, adenocarcinomas). Aberrant crypt foci and hyperplastic/dysplastic polyps likely originate from abnormal growth of colonic crypts in response to aberrant queues in the microenvironment of colonic crypts. Thus, identifying factors which regulate homeostatic versus aberrant proliferation/apoptosis of colonocytes, especially stem/progenitor cells, may lead to effective preventative/treatment strategies. On the basis of this philosophy, the role of growth factors/peptide hormones potentially available in the circulation/microenvironment of colonic crypts is being examined extensively. Since the time gastrins were discovered as trophic (growth) factors for gastrointestinal cells, the effect of gastrins on the growth of normal/cancer cells has been investigated, leading to many discoveries. Seminal discoveries in the area of gastrins and colon cancer as it relates to molecular pathways associated with formation of colonic tumors are reviewed and the possible impact on diagnostic/preventative/treatment strategies is discussed.
Introduction
The gastrin gene was cloned [1, 2] and the sequence of fulllength progastrin (PG) was identified [1] in the early 1980s. The enzymatic steps involved in processing of preprogastrin (product of gastrin messenger RNA) into processing intermediates (nonamidated) and mature (amidated) gastrins (G17/G34) were identified [3•] . Meal ingestion leads to release of gastrins from antral G cells, which stimulate acid secretion into the lumen of the stomach. In the 1980s, C-terminal amidation of gastrin-like peptides [G17/G34/ cholecystokinin (CCK) 8] was defined as a critical step for measuring maximum acid response from parietal cells; nonamidated progastrins were believed to be biologically inactive [4] . However, we now know that nonamidated progastrins are expressed and secreted by many cancer cells, including colon cancer cells [5] . Progastrins are biologically active and exert potent proliferative/antiapoptotic effects on normal colonic crypt cells and significantly increase the tumorigenic/metastatic potential of colonic tumor cells in vitro and in vivo [6] . Sustained hyperproliferation is a risk factor for colon carcinogenesis [7] . Elevated levels of circulating progastrins in animal models cause hyperproliferation of colonic crypts, increase stem cell populations, and increase the risk of colon carcinogenesis in response to DNA-damaging agents [6, 8-10, 11•, 12] or mutation of tumor-suppressor genes (Apc/p53) [13, 14] . Sustained hyperplastic/dysplastic growth of colonic crypts within a focal area of colons, resulting in formation of aberrant crypt foci/ hyperplastic polyps, are the earliest lesions one can diagnose. The multiplicity and size of hyperplastic polyps are associated with the risk of developing adenomas/adenocarcinomas in patients with sporadic colorectal cancers (CRCs) [15, 16] . Genetic/epigenetic molecular pathways associated with the hyperplastic polypadenoma-adenocarcinoma sequence of colon cancer progression has been defined within three or four broad categories ( Fig. 1 ) based on the presence of chromosomal instability, microsatellite instability, and CpG island methylator phenotype [17•] . Expression of gastrin gene/progastrin, although widespread in adenocarcinomas [18] , may be detected in preneoplastic lesions [19, 20•] . Some of the molecular pathways associated with colon carcinogenesis reportedly increase gastrin gene expression [21, 22] , which may explain increasing expression of progastrin during hyperplasia-adenoma-carcinoma stages. Thus, the totality of the literature to-date implicates a role of endocrine/paracrine/autocrine progastrins during different stages of colon carcinogenesis. Endocrine/paracrine progastrins may play a role during formation of hyperplastic growths in a subset of patients positive for sustained levels of circulating gastrins/progastrins (as in hypergastrinemia). The growth of colonic tumors maybe addicted to autocrine progastrins in a small subset of patients [23] , but for most patients autocrine progastrins may mainly impact progression of the disease. Thus, targeting endocrine/autocrine progastrins may help prevent formation of hyperplastic growths and/or reduce resistance to chemotherapeutic agents. Targeting receptor/signaling pathways of progastrins may also provide some benefit. The findings reported in the literature in the past two decades that support the concepts introduced here are presented diagrammatically in Fig. 1 , and are described in the following sections.
Processing Intermediates of Gastrin (Progastrins) Are Autocrine/Endocrine Growth Factors for Colon Cancer/Intestinal Cells Structure-activity studies in the late 1980s suggested that C-terminal amidation was not critical for displacing binding of 3 H-G17 to colon cancer cells [24] . This led to investigation of possible growth effects of nonamidated gastrins (glycine-extended gastrins, G-Gly; fulllength progastrins ). G-Gly was soon established as a mitogenic growth factor for many normal and cancer cells [5, 6, [25] [26] [27] . Simultaneously, several laboratories reported that the gastrin gene is variably expressed by colon cancer cells/adenocarcinomas [5, 6, 28] , and that colon cancers mainly secrete unprocessed/partially processed progastrins [3•, 5, 6, 29, 30] . Significant levels of progastrins were reported in patients positive for CRCs [31] [32] [33] , and were attenuated on surgical removal of the tumors or by inhibiting tumor growth [31, 33] , confirming CRC tumors as a source of circulating progastrins. The availability of specific anti-progastrin antibodies has now confirmed expression of progastrins in colonic adenomas/adenocarcinomas, including hyperplastic polyps [19, 20•] .
The discovery that gastrin gene products are not processed by colon cancers led investigators to generate recombinant full-length human progastrin [34, 35] or transgenic mice. Transgenic mice either constitutively overexpressed G-Gly/human progastrin (G-Gly/hGAS mice) [36, 37] , or overexpressed human progastrin in the intestines in response to fatty acid binding proteins (Fabp-PG mice) [8] [9] [10] ; mice overexpressing amidated gastrins in response to insulin (INS-GAS mice) were also generated [36] . With the help of recombinant human progastrin and transgenic mice, it became evident that G-Gly and progastrin are potent proliferative/antiapoptotic factors for immortalized cell lines in vitro [27, 34, 35, 38] , and for colonic crypts in vivo, resulting in hyperproliferation of colonic crypts [10, 36, 37] .The Cterminal flanking peptide of progastrin has also been recently reported to be biologically active [3•] ; its role in colon carcinogenesis remains to be examined.
Some Colon Cancers May Be Addicted to Autocrine Progastrins
In the mid-1990s it was discovered that downregulation of gastrin gene expression in colon cancer cell lines resulted in attenuation of the growth/tumorigenic potential of more than 60 % of cell lines [23, 39] . However, a complete loss in tumorigenic potential was measured in less than 10 % of cell lines, suggesting that growth of a small percentage of colonic tumors may be addicted to autocrine progastrins. Since then an autocrine role of gastrin gene products has been confirmed by several laboratories [40, 41•] . Antibodies derived against progastrin attenuate growth of gastrin- Fig. 1 Hypothetical model of molecular pathways associated with development of sporadic hyperprolifative/dysplastic/adenomatous growths in the colon: role of endocrine/autocrine progastrins. Pathways 1-3 represent genetic/epigenetic mechanisms believed to be associated with the development of sporadic colonic growths/tumors in humans and rodent models of investigation (reviewed in [17•] ). At least three subtypes of sporadic adenomas have been described, based on phenotype and associated genotype (in terms of microsatellite instability (MSI)/CpG island methylator phenotype (CIMP)/chromosomal instability (CIN); aneuploidy) (reviewed in [17•] ). Many of these genetic/epigenetic changes associated with pathways 1-3 can potentially increase the expression of autocrine progastrins in the colonic growths and serum of patients with colorectal cancers, as described in the text. In addition, a fourth pathway (4), termed "growth factor/cytokine pathway," can significantly increase the risk of developing sporadic colonic growths in response to DNAdamaging agents and/or the indicated genetic/epigenetic changes, leading perhaps to more aggressive growths in a shorter timeframe. Risk factors believed to be associated with the fourth pathway are indicated and may include (1) elevated levels of endocrine/paracrine progastrins, as in hypergastrinemic patients, and (2) elevated levels of cytokines/growth factors associated with inflammation/obesity/specific infections, as discussed in the text. The fourth pathway, associated with a sustained increase in the associated risk factors, likely results in sustained elevation of the indicated intracellular kinases/transcription factors, resulting in hyperproliferation of the affected colonic crypts and possible transformation of the colonic stem cells, significantly increasing the risk of developing dysplastic/neoplastic growths. The roles of specific molecules/pathways presented here were derived from a large number of reports in the literature (referred to in the text). Abs antibodies, ACF aberrant crypt foci, CCK2R cholecystokinin type 2 receptor, CD44 cluster of differentiation 44, CD133 cluster of differentiation 133, CCP clathrin coated pits, CS-ANAX2 cell-surface-associated annexin A2, DCLK1 doublecortin-Ca +2 /calmodulin kinase like protein 1, ERK extracellular-signal-regulated kinase, GG glycine-extended gastrin, HP hyperplastic, IBD inflammatory bowel disease, JAK Janus kinase, LGR5 leucine-rich-repeat-containing G-proteincoupled receptor 5, MAPK mitogen-activated protein kinase, MMR mismatched repair, NFκB nuclear factor κB, PG progastrin, PI3 kinase phosphoinositide 3-kinase, STAT3 signal transducer and activator of transcription 3, Tg transgenic dependent colon cancer cells, whereas anti-G-Gly antibodies are less effective [42•] .
Circulating Progastrins May Be a Risk Factor for CRC
Elevation of the levels of endogenous gastrins/progastrins in rodent models, including transgenic mice (described in the previous section) caused an increase in colon carcinogenesis in response to the carcinogen azoxymethane (AOM) [8-10, 11•, 12, 43, 44] . However, experimental hypergastrinemia or elevation of G-Gly/progastrin levels in transgenic mice, in the absence of carcinogens, did not result in coloncarcinogenesis [45] , suggesting that progastrins/gastrins are not carcinogenic. The total number/multiplicity of aberrant crypt foci were significantly higher in hGAS/Fabp-PG transgenic mice (overexpressing progastrin) compared to that in INS-GAS/wild-type mice (expressing amidated gastrins), which correlated with size and number of colonic adenomas/adenocarcinomas developed in these mice, in response to AOM [8, 9] . Thus, circulating G-Gly and progastrin can potentially function as co-carcinogens and increase the risk of crypt fission/colon carcinogenesis, whereas amidated gastrins alone may be ineffective. Animal studies strongly suggest that hypergastrinemia in itself may not initiate colon carcinogenesis, but elevation of the levels of nonamidated gastrins in the presence of DNA-damaging agents enhances colon carcinogenesis (Fig. 1 ). Processed forms of gastrins are generally present in the circulation. However, in patients with hypergastrinemia due to many different causes (including Zollinger-Ellison syndrome), elevated levels of circulating progastrin are detected [5, 6, 46, 47] , and can potentially increase the risk of tumor development in response to DNA-damaging agents.
Importantly, proliferative/antiapoptotic/co-carcinogenic effects of progastrin were significantly enhanced in proximal colons of transgenic mice; distal colons were much less responsive [8] [9] [10] . In a recent study, however, proximal growths were not observed in AOM-treated transgenic mice [11•] . Although elevated levels of progastrin may increase the risk of proximal colon carcinogenesis, insulin-like growth factors (IGFs) increase the risk of mid-gut to distal colon carcinogenesis in transgenic mice overexpressing IGF-II [48] . Differences in the incidence of proximal versus distal CRCs have been reported in relation to age, gender, and hereditary cancer syndromes [49] . Silencing of mismatched repair genes is significantly higher in proximal versus distal sporadic CRCs [50] . Gene expression profiles of ascending colon versus descending colon are significantly different during embryonic/postnatal development [51] , which may explain differences in susceptibility for developing proximal versus distal colon cancers in response to activation of specific growth factors/molecular pathways.
Mechanisms Mediating Proliferative/Antiapoptotic Effects of Progastrins on Intestinal/Colon Cancer Cells
Following the discovering of the biological effects of progastrins by the turn of the twenty-first century, the past decade has been devoted to delineating receptor/signaling mechanisms mediating growth effects of progastrins.
Target Genes of Gastrins/Progastrins
With use of the method of differential display, it was discovered that cytochrome c oxidase subunit Vb (CoxVb) was specifically upregulated by autocrine/endocrine progastrins [52] . Cytochrome c oxidase is the terminal enzyme complex of the electron transfer chain and is involved in ATP generation [53] . Mammalian cytochrome c oxidase is composed of three major catalytic subunits (I-III), encoded by the mitochondrial genome. In addition, ten smaller regulatory subunits are encoded by the nuclear genome to form the complex cytochrome c oxidase [53] . CoxVb is upregulated during hypoxia, which is relevant to tumorigenesis. Thus, significant differences in expression of specific subunits of cytochrome c oxidase as reported in cancer versus benign/ normal cells (discussed in [52] ) in response to estrogens/ growth factors, such as progastrin, may help the cells meet the high energy requirements of rapidly proliferating cells.
It was also discovered that CoxVb binds cytochrome c [52] . Downregulation of the gastrin gene in colon cancer cells reduced CoxVb levels, resulting in an influx of cytochrome c into the cytosol from mitochondria and activation of proapoptotic enzymes, caspases 3 and 9 [52] . Treatment of Chinese hamster ovary cancer cells with agents that elevate the level of cyclic AMP reduced cytochrome c oxidase activity and released cytochrome c into the cytosol [54] , mimicking the results with progastrin. Thus antiapoptotic effects of endocrine/autocrine progastrin peptides [37, 52] may be mediated by elevation of the levels of CoxVb/ ATP associated with loss of cytochrome c release in the presence of proapoptotic agents, such as AOM. Activation of p65 nuclear factor κB (NFκB) also mediates antiapoptotic effects, resulting in hyperproliferation/colon carcinogenesis of colonic crypts, as described later. Many other target genes are upregulated in response to signaling pathways activated by gastrins/progastrins, including c-Myc, ornithine decarboxylase, cyclin D1, cyclooxygenase-2, vascular endothelial growth factor, and heparin-binding epidermal growth factor (EGF), as described previously [3•, 55-58] .
Intracellular Signaling Pathways
Pathways mediating proliferative/antiapoptotic effects of progastrin/G-Gly were examined by treating cells/mouse models in vitro/in vivo with the peptides or by examining colonic crypts from wild-type versus transgenic (overexpressing progastrin) mice. On the basis of these investigations, we now know that cross talk between several signaling pathways mediates proliferative/antiapoptotic effects of progastrin/G-Gly as presented diagrammatically in Fig. 1 . Early on, the role of Src kinases was investigated. Of the nine Src family members, colonic epithelial cells/ colon cancers only express pp60c-Src and pp62c-Yes (discussed in [59] ). Downregulation of pp60c-Src resulted in loss of malignant potential of colon cancer cells. Since Src proteins are not overexpressed or mutated in colon cancers, it was concluded that Src proteins are probably activated by endogenous mitogen(s). To investigate this possibility, intestinal epithelial cells were stimulated with gastrin/progastrins; the peptides significantly activated c-Src, but not cYes, in the order of progastrin > G-Gly > G17, similar to their growth potencies [59] . Thus, the addition of C-and Nterminal amino acids to G17 increased the biological potency of progastrin peptide Microinjection with anti-c-Src antibodies, confirmed a role of c-Src in mediating growth effects of progastrin/G17 in intestinal cells [59] . Importantly, inhibitory effects of microinjecting anti-Src antibodies were only observed in response to progastrin, but not in response to IGFs or fetal calf serum [59] . Since downregulation of the gastrin gene in gastrin-dependent colon cancer cells attenuated c-Src kinase activity, it is speculated that autocrine progastrins may activate Src kinases in CRCs, imparting a growth potential to the cells. Since these early findings, cross talk between several signaling pathways/ transcription factors-c-Src/phosphoinositide 3-kinase (PI3K)/Akt/Janus kinases/signal transducer and activator of transcription 3 (STAT3)/extracellular-signal-regulated kinases (ERKs)/mitogen-activated protein kinase (MAPK)/ NFκB/Wnt/β-catenin/Notch-has been identified, and may be involved in mediating proliferative/antiapoptotic effects of endocrine/autocrine progastrins [3•, 27, 60, 61] . Some of the more critical pathways are discussed in more detail below.
Patients with CRC tumors positive for high levels of activated p65 NFκB were reported to have high levels of circulating progastrin/IL-8; treatment with cyclooxygenase-2 inhibitors significantly decreased gastrin gene expression/ NFκB activation and reduced serum levels of progastrin/IL-8 [33] . These findings suggested an important role of NFκB in mediating the effects of progastrin. NFκB activation was confirmed to be critically required for mediating growth effects of progastrin in vitro and in vivo downstream of p38 MAPK/ERKs/IKK α/β activation [62, 63•] ; activation of PI3K/Akt may also play an important role [62] .
β-Catenin is also activated in response to endocrine/ autocrine progastrin [64•, 65] . Recent findings suggest that β-catenin activation may be downstream of NFκB, in vitro and in vivo, via direct inhibition of glycogen synthase kinase 3β Tyr 216 phosphorylation (resulting in reduced activation of glycogen synthase kinase 3β) [66•] . Progastrinmediated activation of β-catenin results in increased expression of Jagged-1 (Notch ligand) [65] , and several stem cell markers (discussed below), amplifying the role of progastrin in tumorigenesis (Fig. 1) .
Inflammation (due to inflammatory bowel disease/obesity) [67•, 68•] and infectious agents such as Citrobacter rodentium increase the risk of developing colonic tumors [69•] . Significant synergistic effects of progastrin and Citrobacter rodentium infection were measured on hyperproliferation of colonic crypts in mice in relation to upregulation of ERKs/NFκB/β-catenin [70] . Thus, growth factors such as progastrin may synergize with infectious/inflammatory agents and further increase the risk of colon carcinogenesis (Fig. 1) .
Amidated/nonamidated gastrins apparently bind ferric ions, which may be required for measuring proliferative effects of progastrins, but not amidated gastrins [71] .
Receptor Mechanisms Mediating Biological Effects of Progastrin/G-Gly
Biochemical/pharmacological/physiological evidence strongly suggested that novel receptor mechanisms, distinct from CCK type 1 receptor/CCK type 2 receptor (CCK 2 R), mediate growth effects of nonamidated gastrins [5, 6, 61, 72] .
Cell lines which do not express detectable levels of CCK 2 R were responsive to proliferative/antiapoptotic effects of progastrins [6, 35, 38, 52, [72] [73] [74] . Unlike the antiapoptotic effects of progastrin/G-Gly [26, 38, 62, 63 •], proapoptotic effects of amidated gastrins mediated by wildtype CCK 2 R [75, 76] have been reported. Although proliferative effects of gastrins/progastrins on colonic crypts/colon cancer cells have been reported (as described above), detectable levels of wild-type CCK 2 R have not been measured in these cells [6, 77] . Elevated levels of amidated gastrins in INS-GAS mice had significantly different effects compared with elevated levels of progastrins in hGAS mice [8, 9, 75] , strongly suggesting that CCK 2 R does not mediate the effects of progastrin.
Whereas amidated gastrins and CCK bind CCK 2 R with high affinity, G-Gly and progastrin do not [25, 62, 72] . Therefore, in the quest to find the novel receptor(s) for nonamidated gastrins, several biochemical methods were used. CCK 2 R-independent binding of progastrin with unknown glycosaminoglycan proteins on colonic crypt/intestinal epithelial cells was reported [78] . With use of crosslinking methods, a 36-kDa protein with high affinity in the order progastrin > G-Gly > G17 was identified [79] . Using advanced proteomics, it was discovered that annexin A2 (ANXA2) is the novel 36-kDa, nonconventional "receptor protein" for progastrins/gastrins [74] . Binding of progastrin to ANXA2 was confirmed by co-immunoprecipitation and solution binding assays [74] . Mesenchymal cells around colonic crypts may express CCK 2 R. Therefore, isolated colonic crypts, free of mesenchymal cells, were used to confirm binding of progastrin to ANXA2 on colonic crypt cells of mice overexpressing progastrin [63•] . A recent report suggests that CCK 2 R may be required for measuring growth effects of progastrin on colonic crypts of transgenic mice [11•] . Reports also suggest that progastrins may upregulate expression of CCK 2 R [13] , as previously reported for gastrins [80] . Since no laboratory has demonstrated binding/colocalization of progastrin with CCK 2 R, in vitro or in vivo, it is possible that CCK 2 R, expressed by mesenchymal cells, may indirectly mediate growth effects of progastrin/ANXA2. ANXA2 is a multifunctional protein which binds acidic phospholipids and actin and is involved in intracellular trafficking and kinase activation [81] . ANXA2 has a Cterminal core domain and an N-terminal function domain, which binds several ligands with high affinity, including progastrin [81] . Unlike CCK 2 R antibodies, ANXA2 antibodies blocked growth effects of progastrin [62] . ANXA2 expression was required for measuring growth effects of autocrine progastrin [74] . Since ANXA2 antibodies attenuated growth effects of progastrin, it suggested that progastrin perhaps binds cell-surface-associated ANXA2 (CS-ANXA2). The presence of CS-ANXA2 on many cancer cells has been reported (discussed in [81, 82, Since ANXA2 molecules lack transmembrane domains, mechanisms mediating externalization/internalization of ANXA2/progastrin remain speculative. ANXA2 may be anchored to the surface of cell membranes by ANXA2 receptors [87] , which is essential for metastasis of prostate cancer cells (discussed in [83•] ). Exosomes, secreted by cancer cells, contain annexins, and may be the source of CS-ANXA2 and soluble ANXA2 measured in the conditioned medium and serum of cancer cells/patients (discussed in [83•] ). Exosomal ANXA2 was recently reported to be internalized by raft-mediated pathways in cancer cells and traffic to endosomes [88•] , providing strong evidence that extracellular ANXA2 can be internalized in cells by many different pathways. We now know that progastrin binding of CS-ANXA2 also internalizes CS-ANXA2 via CME [83•] . CME of many peptide/receptor complexes is required for activation of downstream signaling pathways, including MAPK/NFκB pathways (discussed in [83•] ). Effective signal transduction depends on internalization, as opposed to short-term signaling from the cell surface (discussed in [83•] ). Targeting activated receptors to clathrin-dependentendocytosis, rather than non-clathrin-endocytosis, was reported to be necessary for sustained signaling and growth response (discussed in [83•] ). Since sustained activation of NFκB in response to progastrin was required to measure growth effects of progastrin on pancreatic cancer cells [62] , it appears likely that CME of progastrin may mediate the sustained activation of NFκB (Fig. 1) .
Effect of Progastrins on Normal/Cancer Stem Cell Populations
Several cancer/normal stem cell markers, including cluster of differentiation 44 (CD44), cluster of differentiation 133 (CD133), and leucine-rich-repeat-containing G-proteincoupled receptor 5 (Lgr5) are target genes of β-catenin/ Tcf/Lef transcriptional factors [89, 90] . Since β-catenin is activated in response to progastrins, a possible elevation of the levels of stem cell markers was examined in colon cancer cells and colonic crypts of mice in response to autocrine/endocrine progastrins [ It is becoming increasingly evident that targeting cancer stem cells/tumor-initiating cells may prevent relapse of cancer. Selectively targeting cancer stem cells/tumor-initiating cells is being investigated, but this field is as yet in its infancy. It is believed that small populations of neoplastic cells in a tumor are capable of self-renewal and repopulation, and thus developing strategies for targeting cancer stem cells is clinically significant. It is believed that cancer stem cells share many features with adult tissue stem cells, including self-renewal and differentiation [91] ; however, unlike normal stem cells, cancer stem cells lose the ability to produce multilineage differentiated cells. Investigations suggest that progastrin-mediated signaling pathways upregulate expression of stem cell markers within normal colonic crypts and transformed epithelial cells [11•, 41 •, 84•, 85•], giving further credence to the concept that cancer stem cells arise from adult tissue stem cells [91] . Thus, preventing an increase in the expression of stem cell markers/stem cell populations in adult tissues may be an ideal method of preventing progression of cancer.
Gastrin Gene Expression is Increased by Molecular Pathways Associated with Colon Carcinogenesis
Gastrin gene expression is upregulated at the transcriptional level in response to growth factors such as EGF, thyrotropin-releasing hormone, and vasoactive intestinal peptide in transformed endocrine (pituitary/insulinoma) cell lines [92, 93] . It is likely that the gastrin gene is derepressed in transformed endocrine cells and transcription factors involved in upregulating gastrin expression in normal antral G cells are also functional in transformed endocrine cells. In gastrointestinal mucosal cells, expression of peptide hormones (such as gastrin) is normally silenced in the epithelial cells; peptide hormones are expressed only in neuroendocrine cells. Mechanisms that allow derepression of the gastrin gene during colon carcinogenesis in transformed colonic epithelial cells remain unknown. But once the gastrin gene has been derepressed, several growth factors and signaling pathways have been shown to increase gastrin gene expression, resulting in the expression and secretion of progastrins in colonic tumors. Two signaling pathways constitutively upregulated during colon carcinogenesis as a result of either activating (K-ras, β-catenin) or loss of function (Apc) mutations can potentially upregulate gastrin gene expression [13, 14] , providing the molecular basis for the observed increase in gastrin gene expression during colon carcinogenesis.
Constitutive overexpression of gastrin gene/progastrin in embryonic cells, HEK-293, resulted in transforming the cells and imparting tumorigenic/metastatic potential to the cells [85•] , suggesting that overexpression of the gastrin gene, itself, can function as an oncogene in specific cell lineages (such as stem cells/endocrine cells), which may explain the formation of gastric carcinoid tumors in patients with Zollinger-Ellison syndrome. It remains to be determined if formation of a subset of gastrin-dependent colonic tumors is perhaps due to constitutive overexpression of the gastrin gene in these tumors.
Prevention of Autocrine/Endocrine/Co-carcinogenic Effects of Progastrins Using Dietary Agents
There is a large body of evidence demonstrating that many natural dietary products have significant chemopreventive effects, which lends itself to a safe approach for developing preventative and/or therapeutic strategies [94•] . Plant phenolics (curcumin) significantly reduce Apc-associated intestinal-carcinogenesis in Min/+ mice, whereas flavonoids (quercetin) are ineffective [95] . Curcumin [diferuloylmethane; 1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione] is the major pigment in turmeric powder and has antiinflammatory/antioxidant properties [94•, 96•] . Curcumin inhibits chemically induced carcinogenesis during initiation and/or postinitiation phases [97] . Chemopreventative activity of curcumin was also demonstrated during promotion/progression phases of colon carcinogenesis [98] . Activation of NFκB is a crucial event both in inflammation and in cancer [99] . Inhibition of NFκB plays an important role in curcumininduced apoptosis [94•] . Inhibitory effects of curcumin are mediated through the IκB/NFκB pathway in intestinal cells and colon cancer cells [100•, 101] . Curcumin inhibits cell migration of human colon cancer cells through inhibition of NFκB/p65, cyclooxygenase-2 and MMP-2 expression. Constitutive activation of NFκB has been observed in CRC cells but not in normal colorectal epithelial cells [102] . In summary, curcumin suppresses NFκB activation and downregulates expression of NFκB-regulated gene products involved in survival (Bcl2, Bcl-xL, XIAP and cIAP-1), proliferation (cyclooxygenase 2, cyclin D1, and c-myc), angiogenesis (vascular endothelial growth factor and IL-8), invasion and metastasis (intercellular adhesion molecule 1, vascular cell adhesion molecule 1, and endothelial leukocyte adhesion molecule 1) [102] . Since NFκB activation is critically required for mediating the effects of progastrin [62, 63• Curcumin inhibits ligand-induced activation of EGF [106] . Treatment with curcumin plus oxaliplatin significantly inhibits growth of colon cancer cells, associated with decreased expression and activation of EGF receptor (EGFR)/human epidermal growth factor receptor2 /human epidermal growth factor receptor 3 [107] . Since progastrin/ gastrin peptides upregulate EGFR [6] , it is possible that partial growth effects of progastrin are indirectly mediated via upregulation of EGFR. Potent inhibitory effects of curcumin on progastrin-stimulated growth may therefore be additionally mediated via inhibition of EGFR-mediated pathways. Curcumin can potentially regulate physical properties of cell membranes [108] , which may account for the loss of ligand-activated EGFR signaling [106] and inhibition of progastrin-binding/internalization to CS-ANXA2 (unpublished data from our laboratory); however, curcumin did not inhibit binding of IGFs to IGF-I receptor. Thus, curcumin may inhibit interaction of progastrin/CS-ANXA2, which may additionally contribute to curcumin-mediated attenuation of elevated phosphorylated p38 MAPK levels in response to progastrin but not IGF-II [100•].
Diagnostic/Therapeutic Implications of a Role of Autocrine/Endocrine Progastrins in Colon Carcinogenesis
Since most colonic tumors express autocrine gastrins, downregulating gastrin gene expression either with nanoparticles loaded with small interfering RNA against the gastrin-gene or by inducing antisense gastrin messenger RNA expression with the help of viral vectors (for gene therapy) can be used in patients positive for gastrin-dependent (addicted) colon cancers. A patent describing gene therapy for targeting autocrine gastrins was issued [39] , but the therapy has not progressed to clinical trials. Since patients positive for CRC secrete progastrins into the circulation, and high levels of amidated gastrins may also be growth-promoting factors, a vaccine (G17DT) was developed for targeting gastrins. G17DT-conjugate contained nine amino acids from the Nterminal end of G-17 conjugated to diphtheria toxoid. In animal models, G17DT reduced growth and metastatic spread of several gastrointestinal tumors (reviewed in [6] ). However, even though G17DT vaccinations were relatively safe and generated high titers of G17 antibodies, the vaccine did not augment the effects of chemotherapy in patients with advanced gastrointestinal cancers in phase II trials [109] . A vaccine to target full-length progastrins was recently developed [42•] , and was 100 % effective in attenuating growthpromoting effects of autocrine/paracrine progastrins in animal models [110] ; however, the vaccine/antibody approach for targeting endocrine/autocrine progastrins has not reached clinical trials yet. Radiolabeled peptide ligands for membrane receptors are being developed for diagnostic/ therapeutic purposes. Since CS-ANXA2 binds progastrin peptides with high affinity, a labeled progastrin peptide (FAM-PG26) was used to determine if it homes to primary/metastatic tumors, in vivo, in mouse models. Accumulation of FAM-PG26 was localized to focal areas of primary/ metastatic tumors, which reflects overexpression of CS-ANXA2 at these sites, confirmed by ANXA2 staining [85•] . Thus, labeled/conjugated molecules with high affinity for CS-ANXA2 may be useful for diagnosing/treating CRC and other epithelial cancers that are positive for elevated levels of CS-ANXA2. Serum/tumor levels of progastrin can also be used as prognostic markers, as recently reported [20•] .
Rationally designed personalized strategies are required for treating cancer. The results described above heighten the need to examine the inhibitory efficacy of dietary agents in the presence of physiologically/pathologically relevant endocrine/autocrine growth factors. Patients positive for high levels of autocrine growth factors are likely to be less responsive to inhibitory effects of curcumin; tumors positive for expression of autocrine growth factors may require combinatorial treatments to reduce upstream signaling pathways, including MAPK/NFκB/β-catenin/ Notch pathways, for the reasons described above. Recent studies also suggest that curcumin can potentially inhibit growth of cancer stem cell populations [111•, 112•] . In preliminary studies, we measured inhibitory effects of curcumin on cancer stem cell populations expressing DCLK1 and CD44 [103] , strongly supporting this possibility.
Thus, in order to capitalize on our growing understanding of the mechanisms by which autocrine/endocrine progastrins increase the risk of colon carcinogenesis, and increase the tumorigenic/metastatic potential of colonic tumors, several strategies can be developed to (1) target gastrin gene expression by cancer cells, (2) target progastrin peptides using antigen-specific vaccinations, (3) develop tools to inhibit binding of progastrins with CS-ANXA2, (4) develop toxic ligands for binding CS-ANXA2 to specifically target colonic tumors, and (5) develop combinatorial treatment strategies with dietary agents and/or inhibitors of critical signaling molecules.
Conclusions
On the basis of the investigations in the past two decades, several important, paradigm-shifting concepts have taken root in the field of gastrins and colon cancer: (1) nonamidated gastrins are biologically active and exert proliferative/ antiapoptotic/hyperproliferative effects on colonic epithelial cells; (2) colonic growths increasingly express the gastrin gene as the disease progresses through the hyperplasiaadenoma-carcinoma sequence; (3) colonic tumors mainly express full-length progastrins and to a lesser extent G-Gly, with a small percentage expressing amidated gastrins; (4) a subset of colonic tumors may be addicted to autocrine progastrins; (5) elevated levels of nonamidated, but not amidated, gastrins may increase the risk of proximal colon carcinogenesis via specific molecular pathways in patients positive for other risk factors. Additional concepts more recently introduced include the following: (1) endocytosis of progastrins, bound to CS-ANXA2, may be required to measure biological effects of progastrin peptides; (2) several oncogenic pathways mediate growth/co-carcinogenic effects of progastrins; (3) colon cancers expressing high levels of progastrins/CS-ANXA2 may be at higher risk of developing metastatic growths; (3) constitutive overexpression of progastrins may transform stem cells; (4) transformed stem cells, as in colonic tumors, may coexpress CS-ANXA2/ progastrin with DCLK1/CD133/CD44; (5) progastrins may augment the risk of colon carcinogenesis in patients who are also positive for other risk factors such as obesity and inflammatory diseases.
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